Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions

Oral Cancer Clinical Trial

Official title:

Salivary and Serum Levels of Chemerin and MMP-9 in Oral Precancer and Oral Squamous Cell Carcinoma.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02323672
• Other study ID #: chemerin_MMP-9_Oral_cancer
• Status: Completed
• Phase: N/A
• First received: December 18, 2014
• Last updated: February 9, 2017
• Start date: February 2014
• Est. completion date: October 2014

Study information

• Verified date: February 2017
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

45 individuals were subdivided into 3 groups, 15 patients with oral premalignant lesions, 15 patients with oral malignant lesions and 15 control individuals. Levels of chemerin and MMP-9 were evaluated in serum and saliva of these subjects utilizing the ELISA technique.

Description:

45 individuals were subdivided into 3 groups, 15 patients suffering from oral premalignant lesions, 15 patients suffering from oral malignant lesions and 15 individuals having age, gender and periodontal status matched with both patients groups acting as a control group. Serum and whole unstimulated saliva samples were collected from all the included groups in order to determine chemerin and MMP-9 in serum and saliva utilizing the ELISA technique.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: October 2014
• Est. primary completion date: September 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 50 Years

Eligibility

Inclusion Criteria:

• patients with oral premalignant lesions.

• patients with oral malignant lesions.

Exclusion Criteria:

• any systemic disease other than oral premalignant or malignant lesions. smokers. pregnant females. periodontal diseases.

Related Conditions & MeSH terms

• Mouth Neoplasms
• Oral Cancer
• Precancerous Conditions

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

References & Publications (5)

Nanda DP, Dutta K, Ganguly KK, Hajra S, Mandal SS, Biswas J, Sinha D. MMP-9 as a potential biomarker for carcinoma of oral cavity: a study in eastern India. Neoplasma. 2014;61(6):747-57. doi: 10.4149/neo_2014_091. — View Citation

Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, Communi D, Parmentier M, Majorana A, Sironi M, Tabellini G, Moretta A, Sozzani S. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood. 2007 May 1;109(9):3625-32. — View Citation

Skrzeczynska-Moncznik J, Stefanska A, Zabel BA, Kapinska-Mrowiecka M, Butcher EC, Cichy J. Chemerin and the recruitment of NK cells to diseased skin. Acta Biochim Pol. 2009;56(2):355-60. — View Citation

Wang N, Wang QJ, Feng YY, Shang W, Cai M. Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin Oral Investig. 2014 Apr;18(3):997-1004. doi: 10.1007/s00784-013-1046-8. — View Citation

Zhou XJ, Sugerman PB, Savage NW, Walsh LJ. Matrix metalloproteinases and their inhibitors in oral lichen planus. J Cutan Pathol. 2001 Feb;28(2):72-82. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	salivary levels of chemerin in patients with oral premalignant and malignant lesions.		1 day
Secondary	serum levels of chemerin in patients with oral premalignant and malignant lesions.		1 day
Secondary	serum levels of MMP-9 in patients with oral premalignant and malignant lesions.		morning visit
Secondary	salivary levels of MMP-9 in patients with oral premalignant and malignant lesions.		1 day